Results from a analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer.
Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)
Veristrat from Biodesix is an example of a serum-based test used in the clinic that can predict response to a second-line biotherapeutic treatment option.
Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.